Clinical trials have shown that Evinacumab reduced LDL cholesterol by an average of 47% and triglycerides by 55% in patients with HoFH.[9, 10] The expression of ANGPTL3 in the liver is regulated at multiple levels, with reports suggesting that ANGPTL3 is transcriptionally regulated by liver X receptor (LXR).[11] This may partially explain why mice treated with an LXR agonist exhibit increased plasma cholesterol and TG levels.[11]. The gene discussed is ANGPTL3; the disease is homozygous familial hypercholesterolemia.